Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol

Last updated: February 6, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neuroblastoma

Treatment

N/A

Clinical Study ID

NCT05390827
20-330
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to develop a secure method of collecting physiologic information from patients with cancer. The researchers will use this information to learn more about how physiologic data may relate to cancer diagnosis and response to treatment, and to identify factors that may lead to higher or lower risk of cancer.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Project 1: HealthKit

  • Individuals who meet at least one of the following criteria:

  • Diagnosis of new onset early-stage (I-III), low-grade (I-II), or locallyadvanced solid tumor

  • Historical diagnosis of primary invasive solid tumor

  • Diagnosis of metastatic (stage IV) or high-grade (III-IV) disease

  • Enrolled onto an investigational trial in the EDD Service

  • Seen in the MSK UCC from 2021 and onwards

  • Completion of Survivorship Patient Self-Assessment

  • Adult without a history of cancer <50 years of age

  • Adult without a history of cancer ≥ 50 years of age

  • ≥18 years old

  • Own an Apple iPhone with valid iOS operating software

  • Have a registered MSK MyChart account and be willing to download the MSK RemoteMonitoring (RM) application onto their personal iPhone

  • Self-reported "very well" comprehension of written and verbal English language

  • Willing and able to provide informed consent and HIPAA authorization for the releaseof personal health information

Project 2: DigIT-Ex

Individuals who meet one of the following criteria:

  • Patients at MSK who are:

  • Scheduled to undergo any type of BMT (Cohort 1)

  • Diagnosed with new onset AML and scheduled to initiate antineoplastic therapy (Cohort 2)

  • Scheduled to undergo any surgery for prostate cancer (Cohort 3)

  • Scheduled to undergo any lung cancer surgery (Cohort 4)

  • Scheduled to undergo TNT for locally advanced rectal cancer (Cohort 5)

  • Scheduled to initiate androgen deprivation therapy for at least 12 months and hasone of the following prostate cancer diagnoses (Cohort 6):

  • High risk/very high localized, locally advanced,

  • Biochemically recurrent prostate cancer

  • Treatment naïve, low-volume metastatic prostate cancer

  • Scheduled Scheduled to undergo chemotherapy for metastatic pancreatic cancer (Cohort

  • Individuals without cancer <50 years of age (Cohort 8)

  • Individuals without cancer ≥50 years of age (Cohort 9)

  • 18 to 90 years old at the time of consent

  • Willing and able to download the Withings Health Mate app onto their personalmobile device

  • Willing to provide mobile digital physiological data for a period of at leastsix months to a maximum of one year following consent

  • Willing to provide informed consent

Exclusion

Exclusion Criteria:

Project 1: HealthKit

  • Unable or unwilling to successfully export and /or share physiological data

Project 2: DigIT-Ex

  • Unable or unwilling to appropriately use digital platforms or devices

Study Design

Total Participants: 3644
Study Start date:
May 19, 2022
Estimated Completion Date:
July 31, 2027

Study Description

Project 1: HealthKit This prospective registry cohort study will aim to recruit a total of 3,000 patients and 500 adults without a history of cancer. The targeted patient cohorts / settings will aim to be : (1) pre-treatment / during treatment: patients with newly diagnosed early-stage, low-grade, or locally advanced solid tumors that are either pre- or during treatment, (2) post-treatment: patients with primary solid tumor diagnose is that are post-treatment, (3) advanced disease setting: patients diagnosed with metastatic or high-grade disease, (4) patients enrolled onto investigational trials in the early drug development (EDD) Service, (5) patients admitted to Urgent Care Center (UCC), and (6) patients completing a Survivorship Patient Self-Assessment as part of follow-up in an MSK Survivorship clinic. This study will accrue patients receiving care at any MSK site. Adults without a history of cancer will be recruited as a comparison group. The targeted adults without a history of cancer cohorts will aim to be (n=250/cohort): (7) adults without a history of cancer <50 years of age, and (8) adults without a history of cancer aged greater than or equal to 50 years.

Project 2: DigIT-Ex This prospective registry cohort study will aim to recruit a total of 120 patients and 24 adults without a history of cancer. The targeted adult patient cohorts / settings will be (n=12/cohort), excluding cohort 6, which will be (n=48): (1) patients scheduled to undergo bone marrow transplantation, (2) patients newly diagnosed with acute myeloid leukemia (AML), (3) patients scheduled to undergo surgery for localized prostate cancer (4) patients scheduled to undergo surgery for lung cancer, (5) patients scheduled to undergo total neoadjuvant therapy for advanced rectal cancer, (6) patients scheduled to undergo antiandrogen therapy for advanced prostate cancer, and (7) patients scheduled to undergo chemotherapy for metastatic pancreatic cancer. The targeted adults without a history of cancer cohorts will be (n=12/cohort): (8) individuals without a history of cancer aged less than 50 years, and (9) individuals without a history of cancer aged greater than or equal to 50 years.

Connect with a study center

  • Memorial Sloan Kettering Cancer Center

    New York, New York 10065
    United States

    Site Not Available

  • Memorial Sloan Kettering Cancer Center

    New York 5128581, New York 5128638 10065
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.